Molecular Diagnostics Market 2019 | In-depth Analysis by Players Hologic,Inc., Grifols, S.A., Abbott Laboratories, Qiagen N.V., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Becton, Dickinson and Company, and Beckman Coulter, Inc

Molecular diagnostic test are done for diagnosis and drug discovery & development purpose. Molecular diagnostic test results are quick and accurate, which has led to increasing demand for these. In order to cater to growing demand for such tests, manufacturers are more focused on research & development for new product launches.

For instance, in February 2017, AITbiotech Pte Ltd., a Singapore-based genomic service and molecular diagnostics (MDx) company, exhibited its comprehensive range of abTES MDx assays, including its newly launched Zika assays and the multiplex respiratory panel, at MEDLAB 2017, the world’s largest laboratory exhibition and congress in the Middle East.

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1545

Furthermore, in October 2017, FDA approved Roche’s cobas Zika, as first commercially-available donor screening test for Zika virus. In October 2017, QIAGEN launched the custom solution for the molecular diagnostic test, which accelerated adoption of molecular testing for life sciences and molecular diagnostics companies.

In March 2017, Cepheid, Rutgers New Jersey Medical School and FIND announced a new version of the Xpert MTB/RIF test, the Xpert MTB/RIF Ultra (Ultra), for the diagnosis of TB and rifampicin resistance. In August 2017, Selfdiagnostics launched the STD Multitest at MEDICA 2017. STD Multitest is the first and only rapid chlamydia and gonorrhoea duplex disposable molecular test in the world.

In July 2017, Roche announced commercial availability of the cobas HIV-1/HIV-2 for use on the automated cobas 6800/8800 Systems in countries accepting the CE mark. In July 2017, DiaSorin launched a new CE-IVD molecular diagnostic test, Iam CBFB-MYH11 (not available in the U.S.) for ultra-rapid identification of one of the most common genetic causes of Acute Myeloid Leukemia (AML).Therefore, these increasing product launches in molecular diagnostics is expected to foster growth of the market in the near future.

Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1545

Key players in the market are involved in new product launches to cater to increasing demand for molecular diagnostic. For instance, in August 2016 Abbott Laboratories introduced Alinity, a next generation system, used for immunoassay, clinical chemistry, point-of-care, hematology, blood and plasma screening, and molecular diagnostics.

Some of the other key players in the global molecular diagnostics market include Hologic,Inc., Grifols, S.A., Abbott Laboratories, Qiagen N.V., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Becton, Dickinson and Company, and Beckman Coulter, Inc.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.